GlassScriptPhysician profile
Cindy Burns Lee
NPI 1306814256
$3,098.93
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $242 · 2021: $175 · 2022: $465 · 2023: $522 · 2024: $39.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.31 | 2019-2023 | |
| Glaxosmithkline, LLC. | $321.65 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.71 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $243.92 | 2019-2024 | Rybelsus, Ozempic |
| Mylan Specialty L.P. | $201.67 | 2019-2023 | Yupelri, Yupelri |
| Teva Pharmaceuticals USA, INC. | $189.60 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $147.52 | 2019 | |
| Amag Pharmaceuticals, INC. | $134.14 | 2019 | |
| Amgen INC. | $131.85 | 2019-2023 | Evenity, Prolia |
| Abbott Laboratories | $129.21 | 2022-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $124.08 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $116.97 | 2019 | |
| Pfizer INC. | $58.24 | 2019 | |
| Seqirus USA INC | $55.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.50 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $45.74 | 2019-2022 | |
| Agile Therapeutics, INC. | $45.07 | 2023-2024 | Twirla |
| Allergan, INC. | $44.63 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $44.31 | 2019 | |
| Daiichi Sankyo INC. | $42.67 | 2019 | |
| Biodelivery Sciences International, INC. | $39.89 | 2019 | |
| Averitas Pharma INC. | $28.05 | 2023 | Qutenza |
| Dexcom, INC. | $28.02 | 2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $26.88 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $24.12 | 2019 | |
| Esperion Therapeutics, INC. | $22.72 | 2021 | |
| Horizon Therapeutics Plc | $22.65 | 2019 | |
| Smith+Nephew, INC. | $21.63 | 2022 | |
| Amarin Pharma, INC. | $21.61 | 2020 | |
| Exact Sciences Corporation | $20.99 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $17.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.03 | 2019 | |
| Merck Sharp & Dohme LLC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.